Influence of polymer processing technique on long term degradation of poly(ε-caprolactone) constructs

Films, fibers, sponges and disks, based on poly(ε-caprolactone), PCL were prepared using solvent-casting, electrospinning, supercritical fluid processing and melt-compression, respectively. The extent of degradation was determined by measuring the change in morphology, crystallinity and molecular weight (MW). The influence of processing method, MW and drug presence on degradation rate was also evaluated. The different processing techniques produced samples of various morphology and crystallinity. Nevertheless, the differences in degradation rate were not so significant during the advanced stage (18–36 months), while some differences existed during the initial stage (up to 18 months). MW had an important effect on degradation rate, while drug did not. The low MW disks had a degradation rate that was lower by one order of magnitude than high MW constructs

Electrospun Drug-Eluting Fibers for Biomedical Applications

Electrospinning is a simple and versatile method to produce fibers using charged polymer solutions. As drug delivery systems, electrospun fibers are an excellent choice because of easy drug entrapment, high surface area, morphology control and biomimetic characteristics. Various drugs and biomolecules can be easily encapsulated inside or on fiber surface either during electrospinning or through post-processing of the fibers. Multicomponent fibers have attracted special attention because new properties and morphologies can be easily obtained through the combination of different polymers. The factors that affect the drug release such as construct geometry and thickness, diameter and porosity, composition, crystallinity, swelling capacity, drug loading, drug state, drug molecular weight, drug solubility in the release medium, drug–polymer–electrospinning solvent interactions are discussed. Mathematical models of drug release from electrospun fibers are reviewed and strategies to attain zero-order release and control of burst stage are considered. Finally, some results concerning release control in bicomponent fibers composed of poly( ε -caprolactone) and Lutrol F127 (poly(oxyethylene-b-oxypropylene-b-oxyethylene) are presented. The properties of the bicomponent fibers were studied in order to determine the effect of electrospinning processing on crystallinity, hydrophilicity and degradation. Acetazolamide and timolol maleate were loaded in the fibers in different concentrations in order to determine the effect of drug solubility in polymer, drug state, drug loading and fiber composition on morphology, drug distribution and release kinetics. Such electrospun drug eluting fibers can be used as basic elements of various implants and scaffolds for tissue regeneration

Controlled release gelatin hydrogels and lyophilisates with potential application as ocular inserts

Hydrogels and lyophilisates were obtained by chemical crosslinking of gelatin using N-hydroxysuccinimide and N, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride. The systems were characterized with respect to the degree of crosslinking, morphology, water uptake, in vitro drug release and biocompatibility studies. Pilocarpine hydrochloride, a drug for the treatment of glaucoma, was loaded by soaking in an aqueous solution containing the drug. In vitro, the released drug percentage varied between 29.2% and 99.2% in 8 h of study. The release data were fitted to the Korsmeyer–Peppas equation to calculate the release exponent, which indicated anomalous transport for the release of pilocarpine. The corneal endothelial cell culture tests indicated that the prepared biomaterials are not cytotoxic

In vitro and in vivo evaluation of an intraocular implant for glaucoma treatment

Implantable disks for glaucoma treatment were prepared by blending poly(ɛ-caprolactone), PCL, poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) and dorzolamide. Their in vivo performance was assessed by their capacity to decrease intraocular pressure (IOP) in normotensive and hypertensive eyes. Drug mapping showed that release was complete from blend disks and the low molecular weight (MW) PCL after 1 month in vivo. The high MW PCL showed non-cumulative release rates above the therapeutic level during 3 months in vitro. In vivo, the fibrous capsule formation around the implant controls the drug release, working as a barrier membrane. Histologic analysis showed normal foreign body reaction response to the implants. In normotensive eyes, a 20% decrease in IOP obtained with the disks during 1 month was similar to Trusopt® eyedrops treatment. In hypertensive eyes, the most sustained decrease was shown by the high MW PCL (40% after 1 month, 30% after 2 months). It was shown that the implants can lower IOP in sustained manner in a rabbit glaucoma model

Effects of drug solubility, state and loading on controlled release in bicomponent electrospun fibers

Bicomponent fibers of two semi-crystalline (co)polymers, poly(ɛ-caprolactone), and poly(oxyethylene-b-oxypropylene-b-oxyethylene), were obtained by electrospinning. Acetazolamide and timolol maleate were loaded in the fibers in different concentrations (below and above the drug solubility limit in polymer) in order to determine the effect of drug solubility in polymer, drug state, drug loading and fiber composition on fiber morphology, drug distribution and release kinetics. The high loadings fibers (with drug in crystalline form) showed higher burst and faster release than low drug content fibers, indicating the release was more sustained when the drug was encapsulated inside the fibers, in amorphous form. Moreover, timolol maleate was released faster than acetazolamide, indicating that drug solubility in polymer influences the partition of drug between polymer and elution medium, while fiber composition also controlled drug release. At low loadings, total release was not achieved (cumulative release percentages smaller than 100%), suggesting that drug remained trapped in the fibers. The modeling of release data implied a three stage release mechanism: a dissolution stage, a desorption and subsequent diffusion through water-filled pores, followed by polymer degradation control

A poly(ε-caprolactone) device for sustained release of an anti-glaucoma drug

Implantable dorzolamide-loaded discs were prepared by blending poly(ε-caprolactone), PCL, with poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide), Lu. By blending, crystallinity, water uptake and mass loss were modified relative to the pure polymers. Burst was diminished by coating the discs with a PCL shell. All samples presented burst release except PCL-coated samples that showed controlled release during 18 days. For PCL-coated samples, barrier control of diffusion coupled with partition control from the core slowed down the release, while for 50/50 Lu/PCL-coated samples, the enhancement in the porosity of the core diminished partition control of drug release. Nonlinear regression analysis suggested that a degradation model fully describes the release curve considering a triphasic release mechanism: the instantaneous diffusion (burst), diffusion and polymer degradation stages. The MTT test indicated that the materials are not cytotoxic for corneal endothelial cells. A good in vitro–in vivo correlation was obtained, with similar amounts of drug released in vitro and in vivo. The discs decreased intraocular pressure (IOP) in normotensive rabbit eyes by 13.0% during 10 days for PCL-coated and by 13.0% during 4 days for 50/50 Lu/PCL-coated samples. The percentages of IOP decrease are similar to those obtained by dorzolamide eyedrop instillation (11.0%)

Supercritical solvent impregnation of poly(ɛ-caprolactone)/poly(oxyethylene-b-oxypropylene-b-oxyethylene) and poly(ɛ-caprolactone)/poly(ethylene-vinyl acetate) blends for controlled release applications

Poly(ɛ-caprolactone) blends were successfully impregnated with timolol maleate, an anti-glaucoma drug, using a supercritical solvent impregnation (SSI) technique. Supercritical fluid impregnation efficiency results suggested that the best impregnating conditions were obtained when a cosolvent was used and when specific drug–polymer interactions occurred as a consequence of different chemical structures due to polymer blending. Pressure can be either a favourable factor, when there is enough drug affinity for the polymers, or an unfavourable factor when weaker bonding is involved. In order to determine the relative hydrophilicity/hydrophobicity of the blends, contact angle analysis was performed, while crystallinity determination was also useful to understand the obtained release profiles. Drug loading, heterogeneous/homogeneous dispersion of drug inside the matrix, hydrophilicity, crystallinity, all seem to influence the obtained drug release rates. The “in vitro” release results suggested that a sustained drug release rate can be obtained by changing the SSI operational conditions and by modulating the composition of blends, as a mean to control crystallinity, hydrophilicity and drug affinity for the polymer matrix. After a first day burst release, all samples showed a sustained release profile (1.2–4 μg/(ml day), corresponding to a mass of 3–10 μg/day) which is between the therapeutic and toxic levels of timolol maleate, during a period of 1 month. These drug-loaded polymeric matrices can be a feasible alternative treatment modality for the conventional repeated daily administration of eye drops